magAssist is one of the leading innovators of healthcare companies in China. Since our founding in 2017, magAssist has been determined to develop circulatory support devices for acute/severe cardiac and pulmonary failure. Our pipeline includes extracorporeal ventricular assist device (Extra-VAD), percutaneous ventricular assist device (P-VAD), extracorporeal membrane oxygenation systems (ECMO) and organ care systems. Our product MoyoAssist® Extra-VAD has begun multi-center clinical trial in 2020. Starting from 2023, magAssist will release at least one cutting-edge product to the market every year. At magAssist, we work with top-class experts in medicine and engineering around the world to bring the most valuable technology and services for life. Join us! Your participation can save more lives.